Appleby Advised CANbridge Pharmaceuticals on Strategic Share Issuance and Cooperation Agreement

Appleby Advised CANbridge Pharmaceuticals on Strategic Share Issuance and Cooperation Agreement

Appleby has advised CANbridge CARE Pharma Hong Kong Limited (“CANbridge CARE Pharma”), CANbridge (Shanghai) Life Sciences Ltd. (“CANbridge Shanghai”), and Beijing Baheal Zhihe Medical Achievement Transformation Service Co., Ltd. (“Baheal Zhihe”) on a Strategic Cooperation and Exclusive Marketing Service Agreement.

Under the agreement, CANbridge CARE Pharma and CANbridge Shanghai will exclusively engage Baheal Zhihe as the CSO for marketing services for their products—Hunterase®, Livmarli® and Gaurunning®—in Mainland China, Hong Kong, and Macau, subject to upstream licence agreements with the relevant product licensors.

CANbridge is a global biopharmaceutical company leveraging its foundation in China to develop and deliver therapeutics for rare diseases and oncology worldwide, engaging in research, development, and commercialisation of medical products.Baheal Zhihe, a wholly-owned subsidiary of Baheal Wellness Industry, is committed to cultivating medical technology products and solutions with independent intellectual property rights in the PRC, based on the subscriber’s professional commercialisation capabilities, scientific and technological innovation resource integration and incubation capabilities.

The Appleby team was led by Vincent Chan (Partner) of Hong Kong office.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.